Search

Your search keyword '"Sastre-Garriga, Jaume"' showing total 794 results

Search Constraints

Start Over You searched for: Author "Sastre-Garriga, Jaume" Remove constraint Author: "Sastre-Garriga, Jaume"
794 results on '"Sastre-Garriga, Jaume"'

Search Results

1. The influence of MOGAD on diagnosis of multiple sclerosis using MRI

3. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study

6. Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)

9. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

11. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

13. The ageing central nervous system in multiple sclerosis: the imaging perspective.

15. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

17. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

18. Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

19. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

22. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.

23. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

24. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs

26. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria

28. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

29. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.

30. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis

31. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

32. The hippocampus in multiple sclerosis

33. The role of the cerebellum in multiple sclerosis—150 years after Charcot

34. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

35. Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials

38. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

39. Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials

40. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

41. MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis

42. Prognostic value of single-subject grey matter networks in early multiple sclerosis

44. Association of Very Early Treatment Initiation With the Risk of Long-Term Disability in Patients With a First Demyelinating Event

45. Corrigendum to “Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis” [Journal of the Neurological Sciences 449C (2023) Start page–End page/JOTNS D-23-00048R2]

46. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study

48. T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.

49. Prognostic value of single-subject grey matter networks in early multiple sclerosis.

50. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.

Catalog

Books, media, physical & digital resources